Mounjaro cardiovascular outcomes data is still pending (SURPASS-CVOT expected 2029)
The company is headquartered in Vancouver, British Columbia, as indicated by the dateline of the July 14, 2026 announcement
The only requirement is that the drug gets delivered via the subcutaneous or intramuscular route, not intravenously
The compounded ODT may have different bioavailability characteristics since the absorption pathway differs from Rybelsus
ATTAIN-1 (NCT05869903) was a Phase III, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of orforglipron at various doses to placebo in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, who did not have diabetes